Community Trust & Investment Co. Sells 103 Shares of Zoetis Inc. (NYSE:ZTS)

Community Trust & Investment Co. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 0.1% in the 2nd quarter, Holdings Channel reports. The firm owned 87,514 shares of the company’s stock after selling 103 shares during the period. Community Trust & Investment Co.’s holdings in Zoetis were worth $15,071,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Evermay Wealth Management LLC boosted its holdings in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new stake in Zoetis during the first quarter valued at about $26,000. HHM Wealth Advisors LLC grew its position in shares of Zoetis by 1,160.0% in the first quarter. HHM Wealth Advisors LLC now owns 189 shares of the company’s stock valued at $31,000 after purchasing an additional 174 shares during the last quarter. Finally, Tortoise Investment Management LLC increased its stake in shares of Zoetis by 201.5% in the first quarter. Tortoise Investment Management LLC now owns 202 shares of the company’s stock worth $34,000 after purchasing an additional 135 shares during the period. Institutional investors own 89.47% of the company’s stock.

Zoetis Price Performance

NYSE ZTS traded down $0.12 during trading on Tuesday, reaching $179.53. 142,821 shares of the company traded hands, compared to its average volume of 1,971,560. Zoetis Inc. has a 1-year low of $124.15 and a 1-year high of $194.99. The company has a market cap of $82.64 billion, a price-to-earnings ratio of 37.88, a P/E/G ratio of 2.90 and a beta of 0.78. The stock’s 50 day moving average price is $183.65 and its two-hundred day moving average price is $175.28. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.97 and a current ratio of 3.50.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.31 by $0.10. Zoetis had a return on equity of 52.02% and a net margin of 26.92%. The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.16 billion. During the same quarter in the previous year, the firm earned $1.20 EPS. Zoetis’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, analysts anticipate that Zoetis Inc. will post 5.42 EPS for the current year.

Insider Activity

In related news, EVP Robert J. Polzer sold 1,179 shares of Zoetis stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the completion of the transaction, the executive vice president now directly owns 2,353 shares of the company’s stock, valued at approximately $446,928.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at approximately $10,230,034.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert J. Polzer sold 1,179 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $189.94, for a total value of $223,939.26. Following the completion of the transaction, the executive vice president now directly owns 2,353 shares in the company, valued at approximately $446,928.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,930 shares of company stock worth $4,691,799. Corporate insiders own 0.15% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Piper Sandler raised their target price on Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and issued a $205.00 price objective on shares of Zoetis in a research note on Tuesday, September 12th. HSBC began coverage on shares of Zoetis in a report on Wednesday, September 6th. They set a “buy” rating and a $230.00 price objective on the stock. Argus lifted their target price on Zoetis from $190.00 to $201.00 in a research report on Tuesday. Finally, StockNews.com raised Zoetis from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 14th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $222.44.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.